URGN - NASDAQ
UroGen Pharma Ltd.
$26.60
+0.23%UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
At a Glance
Live SnapshotUroGen Pharma Ltd. Management Team
Mr. David Lin
Chief Commercial Officer
Mr. Christopher Degnan CPA
Chief Financial Officer
Compensation
$182,165
Dr. Mark P. Schoenberg M.D.
Chief Medical Officer
Compensation
$639,832
Mr. Michael J. Louie M.D., M.P.H., M.Sc.
Executive Vice President of Medical Affairs & Clinical Development
Mr. James Ottinger R.ph.
Executive Vice President of Regulatory Affairs & Quality
Dr. Marina Konorty Ph.D.
Executive Vice President of Research & Development and Technical Operations
Mr. Bryon Wornson
Executive Vice President of Talent, Advocacy & Communications
Mr. Jason Drew Smith J.D.
General Counsel, Chief Compliance Officer & Corporate Secretary
Compensation
$757,364
Ms. Elizabeth A. Barrett
President, Chief Executive Officer & Director
Compensation
$1,398,747
Mr. Vincent I. Perrone
Senior Director of Investor Relations
UroGen Pharma Ltd. Insider Positioning
During the last 12 months, insiders have sold $650K worth of URGN shares, with no buying activity reported.
3 Months
0
0.00
10.0K
300.00K
-300K
-$300K
3-6 Months
0
0.00
5.1K
99.65K
-100K
-$100K
6-9 Months
0
0.00
10.0K
250.00K
-250K
-$250K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
No buying activity
Top Sellers
Schoenberg Mark
Officer: Chief Medical Officer
$586K
Smith Jason Drew
Officer: General Counsel
$63K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $650K net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
2 insider sellers vs. 0 buyers. Widespread selling across multiple insiders may signal concerns.
Insider Activity Insight
Persistent selling pressure: Consistent insider selling with weak buy/sell ratio suggests insiders may be capitalizing on current valuation. Exercise caution and review recent earnings quality and management commentary.
SEC Filings
URGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2025 N/A | April 30, 2026 | December 31, 2025 | 2025 | |
DEF 14A DEF 14A 2025 N/A | July 15, 2025 | August 11, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | July 01, 2024 | August 07, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | August 01, 2023 | September 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | May 02, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 28, 2021 | June 07, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 29, 2020 | June 08, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | April 26, 2019 | June 03, 2019 | 2019 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.